Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

and Alnylam Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks refer to shares issued by companies that ...

On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.93, for a total transaction of $876,150.00.

West Pharmaceutical Services Total Revenue The stock is down 28.2% since reporting and currently trades at $231.80. Read our full report on West Pharmaceutical Services here, it’s free.

Concerns about potential pharma tariffs began before Trump took office after he repeatedly threatened a 25% tariff.

as evidenced by the stock's significant rise in the trading session. If TNX-102 SL receives approval, it could mark a major milestone for Tonix Pharmaceuticals and offer a new treatment option for ...

While technology is sometimes a hit-or-miss affair, particularly with the intrusions of innovation occasionally outweighing its conveniences, the best pharmaceutical stocks typically enjoy ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

We recently published a list of Was Jim Cramer Right About These 23 Stocks?. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against ...

CRNX Price Action: Crinetics Pharmaceuticals stock is down 2.62% at $35 at publication Tuesday.

Following the announcement, X4 Pharmaceuticals’ stock price declined by 13.49%, closing at $0.295. According to InvestingPro analysis, the company maintains a current ratio of 4.89, indicating ...

Mirum Pharmaceuticals stock has risen nearly 25% since my 'Sell' rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI ...